Abstract
INTRODUCTION
Gastric cancer (GC) is the fourth most common malignancy and the second leading cause of cancer death worldwide [1] . Although metastasis is the major obstacle in the treatment of malignant cancer, the underlying molecular mechanism responsible for GC metastasis needs to be further elucidated.
Human epidermal growth factor receptor 2 (HER2/ ERBB2/neu), a member of the epidermal growth factor receptor family of receptor tyrosine kinases [2] , is overexpressed in 7%-34% of GC cases [3] . Since recent studies have reported a high concordance between HER2 protein overexpression in immunohistochemistry and gene amplification by fluorescence in situ hybridization or chromogenic in situ hybridization [4] , HER2 overexpression seems to be directly correlated with HER2 amplification in most cases [5] . Although our previous study [6] showed that HER2 downregulation decreased cell migration, invasion and metastasis of GC, the efficacy of anti-HER2 treatment of GC patients was limited due to intrinsic and acquired drug resistance. However, the underlying molecular mechanism of HER2-induced GC metastasis remains largely unknown.
Major downstream signaling pathways of HER2 include the mitogen-activated protein kinase (MAPK) pathway and phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT) pathway [7] . MAPKs are serine (Ser)/threonine (Thr)-specific protein kinases and include extracellular signal-regulated kinases (ERKs), p38 MAPK and c-Jun N-terminal kinases (JNKs). After phosphorylation, MAPKs are activated and can translocate to the nucleus followed by regulation of various transcription factors [8] , which control the proliferation, differentiation, survival and migration of specific cell types. The specific role of individual MAPKs is dependent on cell-context and cell-type [9] . Aberrant expression and activation of JNK is found in many cancer cell lines and tissue samples of cancer patients [9] . In general, JNK has been established as a key kinase in cancer cell apoptosis [10] . Recently, the role of JNK in HER2 signaling pathway has gained much attention, because JNK activation plays a critical role in the lapatinib-resistance in HER2-positve breast cancer cells [11, 12] . However, regarding GC, the biological significance of JNK in relation to HER2 signaling has not been reported. Thus, the role of JNK and its interaction with other signaling molecules in HER2-positive GC need to be investigated.
It has been shown that AKT promotes cell migration and invasion of GC cells in vitro [13] and that Akt activation significantly correlates with HER2 expression in GC specimens [14] . Although the association between AKT and JNK in various cancer cells has been reported previously [10, [15] [16] [17] , the results have been inconsistent. In breast cancer cells, AKT induced JNK activation [15] . In lung cancer cells, JNK induced AKT activation [16] . In glioblastoma cells, there was crosstalk between JNK and AKT [10] . In addition, in osteosarcoma cells, JNK inhibited AKT activation [17] . Thus, these findings indicate that the association between JNK and AKT could be different according to the cancer cell type investigated. Thus, interaction of these two molecules in terms of cancer cell metastasis of each cancer type needs to be elucidated. However, the relationship between JNK and AKT in GC has not been described previously.
The present study performed a large scale immunohistochemical analysis and examined the associations between the activation of HER2, JNK and AKT in 423 GC specimens. In addition, we evaluated the in vitro effect of these molecules alone or in combination on the metastatic potential of HER2-positive GC cell lines SUN-216 and NCI-N87. Furthermore, the effect of JNK/AKT inhibition on epithelial-mesenchymal transition (EMT) of these cell lines were investigated since previous studies have demonstrated that EMT plays a critical role in not only tumor metastasis but also drug resistance [18] .
MATERIALS AND METHODS

Patients and tissue array methods
A total of 423 surgically resected gastric carcinoma cases were obtained from the Department of Pathology, Seoul National University College of Medicine from 2 January to 29 December, 2006. Eight paraffin tissue array blocks were prepared as previously described [19] . Briefly, core tissue biopsies (2 mm in diameter) were taken from individual paraffinembedded gastric tumors (donor blocks) and arranged in a new recipient paraffin block (tissue array block) using a trephine apparatus. Each tissue block was able to contain up to 60 cases, allowing eight array blocks to contain 423 cases. The staining results of the different intratumoral areas of gastric carcinomas in these tissue array blocks showed an excellent agreement [20] . A core was chosen from each case for analysis. We defined an adequate case as a tumor occupying more than 10% of the core area. Sections of 4 μm thicknesses were cut from each tissue array block, deparaffinized, and rehydrated. This protocol was reviewed and approved by the Institutional Review Board of Seoul National University.
Immunohistochemistry
Immunohistochemistry was performed after antigen retrieval using a Bond-max automated immunostainer (Leica Microsystems, Newcastle, United Kingdom). The primary antibodies used were against HER2 (1:100, DAKO, Glostrup, Denmark), active form of JNK phosphorylated at Thr183 and Tyr185 (pJNK) (1:50, Cell Signaling Technology, Beverly, MA, United States) and active form of AKT phosphorylated at Ser473 (pAKT) (1:100, New England Biolabs, Beverly, MA, United States). Antibody binding was detected with the Bond Polymer Refine Detection kit (Leica Microsystems). All immunostained sections were then lightly counterstained with Mayer's haematoxylin. Throughout the above analysis, negative controls were prepared by omitting the primary antibody.
For statistical analysis, the results of immunostaining were considered positive if immunoreactivity (nuclear pJNK, and nuclear and cytoplasmic pAKT) was seen in ≥ 10% of the tumor cells, as described in previous studies [20, 21] . Regarding HER2 immunostaining, immunoreactivity was scored in accordance with the HER2 scoring system for GC as described in a previous study [22] . Briefly, cases showing weak to strong staining of the entire or basolateral membrane in ≥ 10% of the tumour cells were considered HER2 immuno-positive.
Cell cultures
Human GC cell lines SNU-216 and NCI-N87 were purchased from the Korean Cell Line Bank (Seoul, Korea). Cells were cultured in RPMI1640 (Life Technologies, Grand Island, NY, United States) supplemented with 10% fetal bovine serum (FBS), 2 mg/mL sodium bicarbonate, 100 U/mL penicillin, and 100 μg/mL streptomycin (Life Technoloiges) at 37 ℃ in a humidified 95% air and 5% CO2 atmosphere.
Lentivirus-mediated short hairpin RNA (shRNA) silencing of HER2 
, and 5'-ACACCTTCTACAATGAGCTG-3' and 5'-CATGATGGAGTTGAAGG TAG-3' for β-actin.
Cell invasion and migration assay
A 24-well Insert System with an 8 μm pore size polyethylene terephthalate membrane was purchased from BD Biosciences. Transwell inserts were coated with Matrigel, followed by rehydration with medium for 2 h. Ten percent FBS-containing medium was placed in the lower chambers to be used as a chemoattractant. removed with a cotton swab. Invasive cells on the bottom surface of the insert were stained with 0.2% crystal violet in 20% methanol for 30 min and were photographed with an inverted microscope. Stained cells were lysed with 10% SDS for 30 min, and absorbance was measured at 570 nm using an ELISA reader (Bio-Rad) as described previously [6] . Migration assays were performed the same way as the invasion assays, using Transwell compartment except that Matrigel was not included [6] .
Assessment of cell growth
SNU-216 (2 × 10
4 cells/each well) and NCI-N87 cells (5 × 10 4 cells/each well) were seeded into 24-well plates and were allowed to grow for 3 d. Cell numbers were measured indirectly by using the crystal violet assay as reported by Kim et al [24] . Briefly, cells were stained with 0.2% crystal violet aqueous solution in 20% methanol for 10 min, dissolved in 10% SDS, transferred into 96-well plates, and the absorbance was measured at 570 nm using an ELISA reader (Bio-Rad, Hercules, CA, United States).
Statistical analysis
For tissue array analysis, statistical analyses were conducted using SPSS version 11.0 statistical software program (SPSS, Chicago, IL, United States), and the χ 2 test was used to determine the correlations between the expressions of HER2, pJNK and pAKT. 
Pharmacological inhibition of JNK and AKT
Cells were seeded and allowed to attach for 24 h. To inhibit endogenous JNK activity, cancer cells were treated with a specific JNK inhibitor SP600125 (20 μmol/L for SNU-216 and 30 μmol/L for NCI-N87) (Cell Signaling Technology) dissolved in dimethylsulfoxide (DMSO). For AKT inhibition, cells were treated with 20 μmol/L of a PI3K/AKT inhibitor LY294002 (Cell Signaling Technology) dissolved in DMSO, as described in previous study [23] .
Semi-quantitative reverse transcription-polymerase chain reaction
Semiquantitative reverse transcription-polymerase chain reaction (SQ RT-PCR) was performed to determine the transcript level of HER2 in human gastric cancer cells, and the amplification of β-actin transcripts was used as the control to normalize the transcript levels of HER2. Total RNAs were isolated using TRIZOL reagent (Invitrogen), and reverse transcription was For cell culture experiments, data were analyzed using GraphPad Prism software for Windows 7 (version 4; GraphPad Software, San Diego, CA, United States), and the significances of the results were determined by the two-tailed Student's t-test. P values of < 0.05 were considered statistically significant for all statistical analyses.
RESULTS
HER2, pJNK and pAKT are positively correlated with each other in GC specimens
To investigate the association between HER2, JNK and AKT in human GC, immunohistochemical tissue array analysis of 423 human GC specimens was performed. Figure 1 shows the representative findings of the immunohistochemical stainings. Cancer cells with membranous HER2 expression were considered to exhibit HER2 activation, and those with nuclear staining of pJNK, regardless of cytoplasmic staining, were considered to exhibit JNK activation. For pAKT staining, immunoreactivity in both nucleus and cytoplasm was interpreted to show AKT activation. We found positive immunoreactivity for membranous HER2 in 56 (14%), pJNK in 130 (31%) and pAKT in 36 (8%) of 423 GC cases, respectively. Data concerning the correlations between the expressions of membranous HER2, nuclear pJNK and pAKT are summarized in Table 1 . HER2 activation was found to be positively correlated with JNK activation (P = 0.035) and AKT activation (P = 0.029). In addition, JNK activation was also correlated with AKT activation (P = 0.025).
Positive crosstalk exists between HER2 and JNK in GC cells
Although a current study [12] reported that HER2 inhibition suppressed JNK activation in HER2-positive breast cancer cells, the relationship between these molecules could be different according to cellular context and cell type. To investigate the direct effect of HER2 on JNK activation, we performed in vitro experiments. Since HER2 protein expression in GC cell lines varied, we selected GC cell lines SNU-216 ( Figure  2A -D) and NCI-N87 ( Figure 2E-H) showing a high level of HER2 expression [6] . To investigate the relationship between HER2 and JNK in GC cells, we first produced stable cell lines infected with lentiviral particles containing non-targeting (control) or HER2-targeting shRNA. Western blot (Figure 2A and E) confirmed that HER2 shRNA overexpression downregulated HER2 activation (manifested by pHER2 expression) and expression in both cell lines. HER2 silencing also decreased JNK activation (manifested by pJNK expression), but not expression. Additionally, double immunofluorescence staining for HER2 and pJNK were performed ( Figure 2B and F) . In both cell lines, control shRNA cells showed immunofluorescence for HER2 at the plasma membrane (red) and pJNK staining in the nucleus (green). In contrast, cells with HER2 silencing showed reduced immunofluorescence for both HER2 and pJNK compared to the control cells.
Next, we examined whether JNK has a role in HER2 activation and expression. Western blot and RT-PCR ( Figure 2C and G) showed that protein expressions of Consistently, immunofluorescence staining ( Figure 2D and H) revealed that SP600125-treated cells showed faint stainability for both pJNK and HER2 compared to DMSO control cells. Taken together, these results indicate that JNK controls and is controlled by HER2 with a positive relationship.
Pharmacological JNK inhibition decreases migration, invasion and EMT of HER2-positive GC cells
To evaluate the effect of JNK on the metastatic potential of HER2-positive GC cells, Transwell assay was performed. Figure 3A shows that SP600125 treatment for 48 h significantly suppressed the cancer cell migration (by 43%, P = 0.0288) and invasion (by 39%, P = 0.005) of SNU-216 cells compared to DMSO control cells. Consistent results were shown in NCI-N87 cells ( Figure 3D ). In the initial steps of metastasis of carcinoma cells, epithelial cancer cells change their phenotype to mesenchymal phenotype and become motile and invasive by a process called EMT [25] . To examine whether JNK activation is related to EMT phenotype of cancer cells, Western blot ( Figure 3B and E) was performed. After SP600125 treatment for 24 h, the expression of the representative epithelial marker E-cadherin enhanced, whereas the expressions of mesenchymal markers Snail, Vimentin and MMP9 reduced. To further confirm these results, immunofluorescence staining was performed. Since actin-dependent membrane protrusions are regarded as a critical determinant of EMT [26] , we examined actin organization. Staining of F-actin with fluorescein isothiocynate-conjugated phalloidin revealed that SP600125 treatment induced apparent changes in actin organization, leading to the loss of many filopodia-like cellular projections shown in DMSO control cells ( Figure 3C and F).
Pharmacological JNK inhibition combined with HER2 shRNA transfection exerts an additive effect on the metastatic potential
The above results indicate that JNK enhances metastatic potential and that positive crosstalk exists between HER2 and JNK in GC cells. To investigate whether the combination of JNK and HER2 has an additive effect on GC cell metastasis, we performed dual inhibition of these molecules. Western blot showed that combination of HER2 downregulation and SP600125 treatment induced lower protein expressions of pHER2 and pJNK than individual inhibitions ( Figure  4A and D) . Consistently, cell migration assay using SNU-216 cells ( Figure 4B) showed that SP600125 
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JNK activation is regulated by AKT activation in HER2-positive GC cells
In GC, AKT has also been previously described as a [27, 28] . Therefore, we investigated whether AKT is involved in HER2/JNK pathway in GC cell lines SNU-216 and NCI-N87. Our data showed that AKT activation decreased in HER2 shRNA transfectants compared to control shRNA transfectants ( Figure 5A and E) .
Next, we observed the correlation between JNK and AKT in these cells. Western blot showed that SP600125 treatment did not change AKT activation manifested by pAKT expression (Figure 5B and F) . In contrast, AKT inhibition by treatment with a PI3K/ AKT inhibitor LY294002 decreased JNK activation in both cell lines ( Figure 5C and G) . These results were confirmed by dual inhibition of AKT and JNK ( Figure 5C and G). These data indicate that AKT is an upstream effector of JNK in HER2/JNK pathway in relation to metastatic potential of HER2-positive GC cells. Additionally, we examined the effect of AKT inhibition on the EMT marker expressions ( Figure 5D and H). Western blot showed that LY294002 treatment increased E-cadherin expression but decreased Snail expression, which demonstrated that AKT increases mesenchymal phenotype.
JNK and AKT co-operatively induce migration of HER2-positive GC cells
To determine the combined effect of JNK and AKT on 
Both JNK and AKT increased cell growth of HER2-positive GC cell lines
Since cell proliferation and survival affects the results of cell migration and invasion, we examined the effect of treatment with either SP600125 (Figure 7A and C) or LY294002 ( Figure 7B and D) on the growth of SNU-216 and NCI-N87 cells. We found that both 
DISCUSSION
Understanding the oncogenic signaling pathways may lead to the development of therapeutic strategies for cancer treatment. In GC, the pivotal role of HER2 metastasis has been shown [6, 29] , but not much is known about the downstream effectors in this process. Although most studies have implicated AKT and ERK as promising therapeutic targets for HER2-positive tumors [27, 28, 30] , JNK, especially in breast cancer, is now emerging as an important molecule in HER2 signaling [11, 12] . In the present study, we found positive associations between HER2, JNK and AKT in terms of GC metastasis. This is the first study, to the best of our knowledge, to show the associations between JNK and HER2/AKT pathway in GC.
In the present study, immunohistochemical tissue array analysis of 423 GC specimens demonstrated constitutive activation of HER2 (14%), JNK (31%) and AKT (8%), which were positively related with each other. In addition, cell culture experiments using HER2-positive GC cell lines SNU-216 and NCI-N87 showed that HER2 silencing by RNA interference reduced JNK activation (manifested by pJNK expression), but not JNK expression. On the other hand, pharmacological inhibition of JNK reduced not only HER2 activation (manifested by pHER2 expression) but also HER2 protein and mRNA expressions. These results indicate that there is a positive reciprocal regulatory loop between HER2 and JNK, and that JNK increases HER2 expression at the transcriptional level, possibly through the regulation of the transcription factor. To the best of our knowledge, this is the first report on crosstalk between HER2 and JNK in the regulation of human cancer cells, including GC cells.
The inter-relationship between the PI3K and MAPK pathways is complex and incompletely understood [30] . Although we previously found that both JNK and AKT are overexpressed in GC tissue specimens [20] , the relationship between these two molecules in GC has not been reported. In the present study, we found a positive association between the activations of JNK and AKT in human GC tissue specimens. In addition, cell culture experiments showed that treatment of HER2-positive GC cells with a PI3K/AKT inhibitor LY294002 decreased JNK activation, whereas JNK did not modulate AKT activation. Since HER2 downregulation suppressed AKT activation, it seems that HER2 inhibited JNK activation in GC cells through PI3K/AKT signaling.
In the present study, we found that pharmacological inhibition of JNK decreased the expressions of Snail, Vimentin and MMP9, but increased the expression of an epithelial marker E-cadherin. Moreover, SP600125 treatment decreased cancer cell migration and invasion. Since similar effects on EMT were induced by both HER2 [6] and AKT, our results indicate that both JNK and AKT might contribute to malignant progression, including metastasis and drug resistance, of HER2-positive GC cells. Although targeted therapies may increase patient selectivity and treatment efficacy, mostly their effects are not durable when they are used alone. For this reason, combination therapies are often needed for effective treatment of malignant tumors. In the present study, we found that treatment with either SP600125 or LY294002 significantly reduced metastatic potential of HER2-positive GC cells to the similar level, and that co-treatment with both of these inhibitors induced a further decrease compared to treatment with either alone. Thus, our findings suggest that combined targeting of JNK and AKT significantly impairs GC cell migration in concert with HER2 downregulation. However, additional animal experiments to evaluate these inhibitions are needed.
In the present study, we found that either inhibition of JNK/AKT suppresses cell growth in both HER2-positive GC cell lines. Thus, JNK/AKT-induced cell growth of these cell lines might affect the results of cell migration and invasion assays observed in the present study. However, our results also indicate that inhibition of JNK/AKT decreases mesenchymal phenotype in individual GC cells based on the EMT marker expressions. Thus, we speculate that JNK/ AKT contributes to metastatic potential as well as cell growth of HER2-positive gastric cancer cells.
In conclusion, our results showed that JNK and AKT are co-expressed in a subset of HER2-positive GC cases, and that HER2, JNK and AKT are positively associated with each other. In addition, inhibition of either JNK or AKT decreased cancer cell motility of HER2-positive GC cells through reversing EMT. Since dual inhibition of JNK and AKT induced more profound effect on cancer cell motility, combined targeting of these molecules might be used to regulate the GC metastasis in a subgroup of GC patients.
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